Haemonetics Corporation (HAE) saw its stock price surge 5.04% in pre-market trading on Thursday following the release of its fourth-quarter fiscal 2025 earnings report. The medical technology company, specializing in blood and plasma-related products, reported better-than-expected quarterly results and provided an optimistic outlook for fiscal year 2026.

For the quarter ended March 31, Haemonetics posted adjusted earnings per share of $1.24, surpassing the analysts' consensus estimate of $1.22. This represents a significant improvement from the $0.90 per share reported in the same quarter last year. The company's revenue for the quarter came in at $331 million, slightly above the Wall Street expectations of $329.38 million. Despite beating estimates, it's worth noting that revenue decreased by 3.7% compared to the previous year.

Looking ahead, Haemonetics provided a strong outlook for fiscal year 2026, projecting adjusted earnings per diluted share in the range of $4.70 to $5.00. This forecast aligns closely with analysts' expectations of $4.93 per share. The company also stated that it is "on track to deliver all of the goals of our four-year long-range plan in fiscal 2026," signaling confidence in its strategic initiatives and growth prospects. Additionally, Haemonetics anticipates revenue growth of 3% to 6% for the upcoming fiscal year, further bolstering investor confidence in the company's future performance.